Cardiology Division Stony Brook University Stony Brook

Stony Brook, United States

Cardiology Division Stony Brook University Stony Brook

Stony Brook, United States
SEARCH FILTERS
Time filter
Source Type

Butler J.,Cardiology Division Stony Brook University Stony Brook | Hamo C.E.,Cardiology Division Stony Brook University Stony Brook | Filippatos G.,National and Kapodistrian University of Athens | Pocock S.J.,London School of Hygiene and Tropical Medicine | And 24 more authors.
European Journal of Heart Failure | Year: 2017

Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health concerns contributing to major medical and economic burdens to society. T2DM increases the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. Several anti-hyperglycaemic medications have been associated with a concern for worse HF outcomes. More recently, the results of the EMPA-REG OUTCOME trial showed that the sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin was associated with a pronounced and precocious 32% reduction in cardiovascular mortality in subjects with T2DM and established cardiovascular disease. These benefits were more related to a reduction in incident HF events rather than to ischaemic vascular endpoints. Several mechanisms have been put forward to explain these benefits, which also raise the possibility of using these drugs as therapies not only in the prevention of HF, but also for the treatment of patients with established HF regardless of the presence or absence of diabetes. Several large trials are currently exploring this postulate. © 2017 The Authors European Journal of Heart Failure.

Loading Cardiology Division Stony Brook University Stony Brook collaborators
Loading Cardiology Division Stony Brook University Stony Brook collaborators